JDP Therapeutics Initiates Clinical Trial with Its Lead Candidate JDP-205

Share Article

JDP Therapeutics Inc., a specialty pharmaceutical company, announced today that the first group of 12 human volunteers have been dosed JDP-205 Investigational New Drug in a phase I clinical trial without any significant adverse events.

News Image
This is the first time that JDP-205 injection is being administered in a human trial.

Past News Releases

RSS

JDP Therapeutics Inc., a specialty pharmaceutical company, announced today that the first group of 12 human volunteers have been dosed JDP-205 Investigational New Drug in a phase I clinical trial without any significant adverse events. This clinical trial is a single dose, randomized, 4-way crossover study in healthy normal volunteers. It is designed to evaluate the safety, tolerability, and pharmacokinetic properties of the company's lead product, JDP-205. The Company plans to enroll 24 volunteers for the trial. “This is the first time that JDP-205 injection is being administered in a human trial, a major milestone for the Company. We are excited in advancing the development program of JDP-205,” commented Jie Du, Ph.D. President of JDP Therapeutics.

JDP’s first program, JDP-205 is a proprietary product being developed for the treatment of allergic reactions for the hospital market. A survey of 110 physicians revealed that 86% of responding doctors had indicated readiness to use JDP-205 when it is approved by the FDA. A second independent study with in-depth clinician interviews confirmed the findings.

Allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates but with very limited selections of medications. JDP-205 will offer an alternative treatment to the current therapy for the first time in over 55 years.

JDP Therapeutics Inc, founded in 2008, is a clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for acute care use in the hospital setting.

For further information, please call 215-661-8557 or email info(at)jdptherapeutics(dot)com

Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP’s product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP’s ability to fund such efforts with or without partners, and other risks.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jonathan Black
Visit website

Media